Written by: Madhu Nag, PhD, Chief Scientific Officer at InSphero
Introduction
Over the past decade, organoids and other complex human in vitro models have moved from conceptual promise to practical utility across biomedical research. Their ability to recapitulate aspects of human tissue architecture, cellular heterogeneity, and functional response has fundamentally reshaped how disease mechanisms and therapeutic responses can be studied. Yet, despite this progress, the field has faced a persistent bottleneck: insufficient standardization to support reproducibility, scalability, which in turn leads to a lack in regulatory confidence.
The launch of the NIH Standardized Organoid Modeling (SOM) Institute marks a pivotal inflection point. By prioritizing standardized protocols, benchmarking frameworks, and shared infrastructure, the National Institutes of Health is making a clear statement: advanced human in vitro models are no longer peripheral research tools, but essential components of a modern, regulatory-aware biomedical ecosystem. The center’s core mission is to serve as a neutral scientific hub, generating organoid models and protocols that are reproducible, reliable, and easily accessible. By generating data from models that replicate the structure and function of human organs, the center aims to produce precise results and minimize variability, thereby accelerating drug discovery.
Standardization as a Prerequisite for Translation
Organoids are inherently complex biological systems. Differences in cell sourcing, differentiation protocols, culture conditions, and endpoint selection have historically limited cross-laboratory reproducibility and validation, thereby hindering confidence in downstream decision-making. These limitations become especially consequential when organoids are used to inform translational safety or efficacy assessments.
The SOM Institute addresses these challenges by focusing on:
- Defined, reproducible manufacturing and culture standards
- Biologically and physiologically anchored performance metrics
- Transparent benchmarking across model types and laboratories
This approach reframes organoids not as bespoke experimental systems, but as engineered biological platforms - capable of supporting rigorous, reproducible science at scale.
Alignment with the FDA Modernization Acts 2.0 and 3.0
The timing of the SOM Institute is not coincidental. Its launch directly aligns with the paradigm shift codified by the FDA Modernizations Act 2.0 and 3.0. The FDA Modernization Act 3.0 builds directly on the foundation laid by Act 2.0 by moving beyond permissive language and into implementation. While Act 2.0 formally opened the door for the use of non-animal testing methods, Act 3.0 closes long-standing regulatory gaps by requiring the FDA to actively operationalize these approaches. This includes establishing clear qualification pathways for New Approach Methodologies (NAMs), defining timelines for reducing reliance on legacy animal testing, and increasing transparency around their adoption in regulatory review.
Critically, these Acts did not lower scientific standards, they raised them. They shifted the emphasis from historical precedent toward predictivity, human relevance, and context of use. In this environment, all non-animal, human 3D in vitro models must meet clearly defined criteria for robustness, reproducibility, and interpretability if they are to meaningfully support regulatory submissions.
The SOM Institute provides the missing infrastructure needed to operationalize this vision. By establishing reference standards and qualification-ready data frameworks, it creates a bridge between innovation and regulatory acceptance.
Regulatory Convergence and the Role of Shared Standards
Beyond the U.S., regulatory agencies worldwide are moving toward convergence around human-relevant testing strategies. Harmonization efforts among agencies such as the U.S. Food and Drug Administration, EMA, and PMDA increasingly emphasize aligned expectations for data quality, transparency, and biological relevance.
Standardized organoid models developed and benchmarked under the SOM framework, have the potential to serve as globally interpretable systems. This is essential for multinational drug development programs, where inconsistent model performance across different regions introduces unnecessary risk and redundancy. In this sense, SOM is not merely a scientific initiative; it is enabling infrastructure for global regulatory science.
InSphero’s Strategic Alignment: Integration, Expansion, and Platform Thinking
At InSphero, this shift toward standardized, human-relevant biology is not aspirational, it is operational. The integration of DoPPL into the InSphero ecosystem and the deliberate expansion of our portfolio to include both spheroid- and organoid-based systems reflect a long-term commitment to platform integration rather than isolated model development.
By combining scalable 3D microtissues with advanced perfused and multi-organ systems, and by extending these capabilities into organoid biology, we are building an integrated continuum of complexity:
- From robust, high-throughput screening systems
- To more physiologically complex, context-specific models
- Anchored by shared standards, endpoints, and data architectures
This approach mirrors the vision articulated by the SOM Institute and responds directly to the expectations set by regulatory modernization: that human-relevant models must be fit for purpose, interoperable, and supported by reproducible engineering principles.
Implications for Industry, Academia, and Regulators
For industry, the convergence of SOM standards and regulatory modernization enables more confident decision-making earlier in development, reducing late-stage attrition driven by human-specific liabilities.
For academia, standardized frameworks free researchers to focus on biological innovation while ensuring that discoveries are translatable beyond individual laboratories.
For regulators, standardized organoid systems offer a path toward consistent, interpretable datasets that can complement and, in some cases, outperform traditional animal models, particularly in areas where species differences limit predictivity.
Conclusion
The NIH Standardized Organoid Modeling Institute represents more than an investment in organoid science; it is a structural commitment to the future of human-relevant, regulatory-ready biology. When viewed alongside the FDA Modernization Acts and growing global regulatory convergence, SOM emerges as a cornerstone initiative that enables NAMs to move from promise to practice.
InSphero’s integration of DoPPL and expansion into organoid technologies reflects this same philosophy: that the future of biomedical research lies not in isolated models, but in integrated, standardized platforms capable of supporting rigorous science, translational confidence, and regulatory trust. Together, these efforts signal a decisive step toward a more predictive, humane, and globally aligned biomedical research paradigm.
